HOME > LATEST
LATEST
-
BUSINESS 25 Japan Drug Makers’ Total Operating Profit Tops 2 Trillion Yen for 1st Time: Tally
May 20, 2025
-
REGULATORY LDP Project Team Eyes Coverage Discussions for Drug Use in Pre-Symptomatic Stage
May 20, 2025
-
REGULATORY New Stelara Biosimilars Earn May Listing, Eylea Follow-On Takes Pass Again
May 20, 2025
-
REGULATORY Japan Approves Moderna RSV Vaccine, GSK’s ADC, and More
May 20, 2025
-
BUSINESS Chugai’s PNH Drug PiaSky Approved in Taiwan
May 20, 2025
-
COMMENTARY Impact of US Drug Policy: President Trump Shaking the World of Pharma
May 19, 2025
-
BUSINESS Japan’s Big 4 Wholesalers Log Operating Margin of 1.24%, All Break 1% Mark: Tally
May 19, 2025
-
ORGANIZATION At JPA’s Behest, FPMAJ Asks Members to Align Packaging with Approved Dosages
May 19, 2025
-
BUSINESS Sawai Wins Lawsuit over CML Use in Sprycel Generic
May 19, 2025
-
BUSINESS Boehringer Ingelheim, Kanagawa Join Hands in Disease Prevention
May 19, 2025
-
BUSINESS AstraZeneca, Nara City Form Partnership in NCDs
May 19, 2025
-
BUSINESS Seikagaku Eyes FDA Re-Filing of Herniated Disk Drug within 1 Year
May 19, 2025
-
ORGANIZATION PhRMA Raps Japan’s Drug Price Controls as Non-Tariff Trade Barriers, Urges US Govt Action
May 19, 2025
-
REGULATORY Ex-Lawmakers’ Club Proposes CEA Overhaul, GDP-Linked Drug Spending
May 16, 2025
-
BUSINESS Eisai Aims to Turn Leqembi to Black in FY2026 with EU Approval as Tailwind: CEO
May 16, 2025
-
REGULATORY Ex-PM Kishida Stresses Need to Bolster Innovation in Japan: Tokyo Speech
May 16, 2025
-
REGULATORY Biktarvy Gets Label Update to Add Eligible Patients
May 16, 2025
-
REGULATORY Regional Formulary Push Pops Up from Ishin at 3-Party Talks
May 16, 2025
-
BUSINESS Quviviq Retains Top Slot in Rep Calls for GPs: Intage March Data
May 16, 2025
-
BUSINESS ASKA Filed Switched OTC of Emergency Contraceptive Last June
May 16, 2025
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…